RenovoRx, Inc. (RNXT)

1.2600 +0.0400 (+3.28%) At close: 04:00PM EDT

RenovoRx, Inc.

4546 El Camino Real
Suite B1
Los Altos, CA 94022
United States
650 284 4433
https://renovorx.com

Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 8

Key Executives

Name	Title	Pay	Exercised	Year Born
Dr. Ramtin Agah M.D.	Founder, Chairman of Board & Chief Medical Officer	332.89k	N/A	1966
Mr. Shaun R. Bagai	CEO, Secretary & Director	589.38k	N/A	1977
Ms. Leesa Gentry	Chief Clinical Officer	N/A	N/A	1970

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

RenovoRx, Inc., a clinical-stage biopharmaceutical company, focuses on developing proprietary targeted combination therapies to improve therapeutic outcomes for cancer patients undergoing treatment. Its lead product candidate is RenovoGem, an oncology drug-device combination product, consisting of intra-arterial gemcitabine and RenovoCath that is in Phase III clinical trials for the locally advanced pancreatic cancer. The company has a research collaboration with Imugene Limited to deliver oncolytic virus therapy for the treatment of difficult-to-access tumors. RenovoRx, Inc. was founded in 2009 and is headquartered in Los Altos, California.

Corporate Governance

RenovoRx, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.